ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the cancer from coming back in patients who are ctDNA-positive or who have evidence of cancer after treatment and surgery.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Dobry ogólny stan zdrowia (mogą pracować, mogą mieć małe ograniczenia)
- •Zaawansowany rak płuca (stadium IB, II lub IIIB), który można usunąć chirurgicznie
- •Dostępny materiał guzów do badań laboratoryjnych
- •Chory będzie leczony chemioterapią i immunoterapią przed operacją
✗ Disqualifies
- •Rak, który nie można operować lub rozszerzył się na inne organy
- •Wcześniejsze leczenie chemioterapią, radioterapią lub immunoterapią
- •Określone mutacje genetyczne w komórkach raka (EGFR lub ALK)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Miami
Miami, United States
Trial contact
Richa Dawar, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.